impede the task of haematologists. Therefore, reporting lymphomas combined with chyloperitoneum facilitates the choice of appropriate treatment and the outcome comparison between similar incidents.
A 38-year-old man with 3-month recurrent effusive right pleuritis, after being initially treated for presumed tuberculosis, was referred to our centre. The patient had increasing abdominal distention and shortness of breath. Physical examination revealed ascites, left axillary lymphadenopathy and upper limb oedema. Lymph node biopsy was diagnostic of peripheral T-NHL, unspecified. There was complete effacement of the nodal architecture, along with infiltration by neoplasmatic, lymphoid cells with abundant mitotic figures. They were medium-sized or enlarged with slightly eosinophilic cytoplasm and irregular-shaped nuclei. Immunohistochemically, tumour cells were strongly positive for CD5, mildly positive for CD3 and negative for CD20, CD79a, CD30, CD56, CD23 and cyclin D1 (Fig. 1) . Peripheral, unspecified T-NHLs derive from post-thymic T cells at various differentiative stages. Computed tomography (CT) scan revealed ascites, ambilateral pleuritic fluid causing mediastinal compression, pericarditis and excessive left axillary, mediastinal, mesenteric and retroperitoneal lymphadenopathy (Fig. 2) . Enlarged lymph nodes surrounding the thymus were traced. The presence of pericardial fluid was confirmed by an echocardiogram. Paracentesis elicited chylous-effusive pleuritic fluid and creamy white ascetic fluid with elevated triglycerides (1,212 mg/dl), low protein (2.6 g/dl) and cell count (550 cells per decilitre) with lymphocytic predominance.
Moreover, thrombosis was detected in the left brachiocephalic, subclavian and internal jugular veins, as a result of the CT scan. Simultaneously, after inflammation of the right thigh skin was traced, color-flow Doppler ultrasonography revealed extensive thrombosis of the right femoral and popliteal veins (Fig. 3) . D-dimers (382.6 ng/ml) and fibrinogen levels (791.6 mg/dl) were elevated. Protein S, protein C, antithrombin III and homocysteine levels were within normal range. No anti-phospholipoid antibodies or factor V Leiden mutation was present. Therefore, severe thrombosis was attributed to aggressive T-NHL.
The ; 30 mg, three times weekly, for 6 weeks) was the final therapeutic approach [3] . Eighteen months after diagnosis, the patient died, due to thrombopaenia, resulting in fatal gastrorrhagia. Despite rarity of lymphoma-caused chyloperitoneum, some cases have been reported. A case of Hodgkin's disease presenting with chylous ascites and cavernous transformation of the portal vein has been described [4] . Moreover, symptomatic enterocele as an unusual presentation of chylous ascites and follicular lymphoma has been reported recently [5] . There is a lack of data regarding appropriate treatment of T-NHLs, which develop the complication of chylous ascites. The prognosis is dismal. The majority of patients die within a few months, regardless of chemotherapy [1] .
Despite fatal outcome, our patient survived 18 months, which is much longer than the expected 3 to 6 months, and became free of ascites for 5 months. This rare case shows the efficacy of CHOEP regimen, even in aggressive NHLs of young patients, which present with systemic complications and are characterized by bad prognosis. Furthermore, our patient received full average relative chemotherapy dose intensity (ARDI), as the administered dosage of all regimens was exactly equivalent to the dosage planned by our initial protocol. Thus, ARDI in our patient was 100%, which was an important goal achieved, regardless of the patient's death. When ARDI is less than 90%, NHL patients are at risk of reduced survival [6] . In conclusion, more clinical trials testing new chemotherapy combinations and novel drugs are needed for increasing treatment options in aggressive T-NHLs of young patients. The latter will lead to better dosing schemes and therapeutic results. 
